Cell Biology Program
The Lydia Finley Lab
Research
The Finley Lab investigates how cellular metabolic pathways regulate cell fate decisions in stem cells and cancer cells. We combine genetic and metabolomic approaches to investigate cell-type specific growth requirements and elucidate how flux through central metabolic pathways regulates key cellular activities, including self-renewal and differentiation. In particular, we are interested in understanding how changes in metabolite availability shape the chromatin landscape to influence gene expression programs that control cell survival, growth and differentiation. Our work aims to answer fundamental questions about how cells regulate the commitment to differentiation and how failure to execute terminal differentiation can underlie diseases such as cancer.
Featured News
Publications Highlights
A non-canonical tricarboxylic acid cycle underlies cellular identity. Arnold PK, Jackson BT, Paras KI, Brunner JS, Hart ML, Newsom OJ, Alibeckoff SP, Endress J, Drill E, Sullivan LB, Finley LWS. Nature. 603: 477-481. 2022.
Amino acid intake strategies define pluripotent cell states. Todorova PK, Jackson BT, Garg V, Paras KI, Chen Y, Baksh SC, Yan J, Hadjantonakis, A, Finley LWS. Nature Metabolism. 6: 127-140. 2024.
People
Lydia Finley, PhD
Geoffrey Beene Junior Faculty Chair
- Lydia Finley studies the mechanisms that link metabolic pathways to cell fate decisions.
- PhD, Harvard University
- BS, Yale University
- [email protected]
- Email Address
- 212-639-6722
- Office Phone
Members
- Phd in Immunology, Medical University of Vienna
- BS, Duke University
- B.S.
Lab Alumni
Lab Affiliations
Achievements
- New York Stem Cell Foundation – Robertson Investigator (2023)
- Louise and Allston Boyer Young Investigator Award for Basic Research (2022)
- National Cancer Institute R37 MERIT Award (2020)
- Pershing Square Sohn Prize for Cancer Research (2020)
- Searle Scholar (2018)
Read more
- Dale F. Frey Breakthrough Award of the Damon Runyon Cancer Research Foundation (2017)
Lab News & Events
Accolades
Team Recognitions
-
Julia Brunner, Kravis WiSE Fellowship (2024)
-
Abby Xie, NIH/NCI F31 (2023)
-
Paige Arnold, Gerstner Sloan Kettering Chairman’s Prize (2022)
-
Paige Arnold, Weintraub Award (2022)
-
Sanjeethan Baksh, STAT Wunderkind (2022)
-
Benjamin Jackson, NIH/NICHD F31 (2022)
-
Katrina Paras, Bruce Charles Forbes Pre-Doctoral Fellowship (2021)
-
Benjamin Jackson, Gerstner Sloan Kettering Grayer Fellowship (2021)
-
Julia Brunner, Human Frontier Science Program Fellowship (2021)
-
Sanjeethan Baksh, Olaf S. Anderson Physician-Scientist Award (2021)
-
Paige Arnold, NIH/NICHD F31 (2019)
-
Jossie Yashinskie, AACR Minority Scholar in Cancer Research Award (2018)
-
Jossie Yashinskie, NIH/NICHD T32 fellowship (2018)
Open Positions
To learn more about available postdoctoral opportunities, please visit our Career Center
To learn more about compensation and benefits for postdoctoral researchers at MSK, please visit Resources for Postdocs
Career Opportunities
Get in Touch
-
Lab Head Email
-
Office Phone
-
Office Fax
-
Lab Phone
-
Lab Fax
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Lydia Finley discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].